Financial Performance - The company reported a revenue of RMB 500 million for the first half of 2023, representing a 20% increase compared to the same period last year[23]. - The company's operating revenue for the first half of 2023 was ¥142,122,680.52, representing a 16.58% increase compared to ¥121,908,040.10 in the same period last year[35]. - The basic earnings per share increased by 24.32% to ¥0.0046 from ¥0.0037 year-on-year[29]. - The net profit attributable to shareholders reached CNY 2.1554 million, up 44.60% year-on-year[79]. - The company aims to achieve a net profit of RMB 80 million for the full year 2023, which would represent a 10% increase from 2022[23]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, decreased by 1,743.75% to -¥12,365,873.60 from ¥640,352.06 in the previous year[29]. - The company reported a net profit of ¥2.16 million for the first half of 2023, but has not yet achieved overall profitability, with a net profit attributable to shareholders of ¥12.37 million after excluding non-recurring gains[93]. Research and Development - The company has allocated RMB 100 million for R&D in new technologies, focusing on minimally invasive procedures and advanced imaging techniques[23]. - The total R&D investment reached CNY 53,728,136.74, a year-on-year increase of 29.62%[62]. - Research and development expenses accounted for 37.80% of operating revenue, an increase of 3.80 percentage points compared to 34.00% in the previous year[29]. - The number of R&D personnel increased to 158, with the proportion of R&D staff in total employees at 28.83%[67]. - The average salary of R&D personnel rose to CNY 41.68, reflecting a significant increase from CNY 33.99 in the previous year[67]. - The company has developed a high-precision positioning navigation technology with an average positioning accuracy error of less than 1mm, achieving performance levels comparable to imported high-end products[49]. - The company is actively developing new technologies in the field of electrophysiology, including pressure-sensing catheters and cryoablation systems[76]. Market Expansion and Strategy - The company plans to expand its market presence in Europe and North America, targeting a 25% increase in market share by the end of 2024[23]. - Strategic partnerships with leading hospitals are being established to enhance product adoption and clinical validation, with a goal of increasing collaboration by 40%[23]. - The company is exploring potential acquisitions to bolster its product portfolio and expand its technological capabilities in the electrophysiology sector[23]. - The company’s products are now registered in multiple countries, including the EU, South Korea, and Brazil, expanding its international market presence[78]. - International market revenue grew by over 60%, with the company expanding its presence to 31 countries and regions, and registering 11 new products in 4 countries[85]. Product Development and Innovation - New product launches are expected to include a next-generation 3D electrophysiology mapping system, anticipated to enhance diagnostic accuracy by 30%[23]. - The company has launched the TrueForce® pressure catheter, which has been used in over 300 procedures since its approval in February, receiving positive feedback from numerous medical centers[83]. - The company has five innovative products in the special approval process for innovative medical devices[76]. - The company has established an energy treatment technology platform to achieve breakthroughs in radiofrequency and cryoablation technologies[50]. - The company has introduced a multi-channel temperature detection technology that alerts operators when temperatures exceed safe levels during ablation procedures[178]. Financial Position and Assets - The total assets at the end of the reporting period were ¥1,799,531,340.35, reflecting a 0.63% increase from ¥1,788,331,481.27 at the end of the previous year[35]. - The net assets attributable to shareholders at the end of the reporting period were ¥1,680,802,538.11, a slight increase of 0.32% from ¥1,675,493,863.92 at the end of the previous year[35]. - Cash and cash equivalents increased by 31.41% to 768.58 million RMB, accounting for 42.71% of total assets[96]. - Accounts receivable rose by 50.78% to 54.18 million RMB, representing 3.01% of total assets[96]. - Inventory increased by 20.40% to 104.72 million RMB, which is 5.82% of total assets[96]. Risk Factors and Challenges - Risk factors identified include regulatory changes and market competition, with mitigation strategies outlined in the management discussion section[23]. - The company faced significant competition from foreign brands, which hold over 80% of the market share in the electrophysiology medical device sector[94]. - The company is at risk of core technical talent loss due to increasing competition for skilled professionals in the medical device industry[94]. - The company reported a net cash outflow from financing activities of 5.51 million RMB, primarily due to new factory rental payments[98]. - The company is actively responding to supply chain impacts from bulk purchasing and international situations by stockpiling key raw materials[98]. Shareholder Commitments and Governance - The company is committed to ensuring shareholder returns and has detailed profit distribution policies in place, prioritizing cash dividends[42]. - The company has commitments from major shareholders, including Jiaxing Huajie and Micron Investment, regarding share lock-up and reduction intentions, ensuring compliance with regulations[148]. - The company has established a commitment to stabilize stock prices for three years post-IPO, including a buyback of up to 2% of total shares within a 12-month period if necessary[144]. - The company has confirmed that all commitments made by shareholders and management have been fulfilled in a timely and strict manner[141]. - The company has committed to not transferring shares for three complete accounting years post-IPO unless certain profitability conditions are met[144].

证券代码：688351 证券简称：微电生理 公告编号：2023-016 上海微创电生理医疗科技股份有限公司 第三届监事会第四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 上海微创电生理医疗科技股份有限公司（以下简称"公司"）第三届监事会 第四次会议（以下简称"本次会议"）于2023年8月17日以现场结合通讯方式， 由监事会主席CHENGYUN YUE（乐承筠）女士主持召开。本次会议通知于2023年8 月7日通过电子邮件向各位监事发出，应出席监事3人，实际出席监事3人，董事 会秘书列席会议。本次会议的召集、召开程序符合《中华人民共和国公司法》、 《公司章程》等相关规定。 二、监事会会议审议情况 1、审议通过《关于2023年半年度报告及其摘要的议案》 公司《2023 年半年度报告》和摘要的编制和审议程序符合相关法律法规及 《公司章程》等相关规定，公允反映了公司 2023 年半年度的财务状况和经营成 果；在编制过程中，未发现公司参与报告编制和审议的人员有违反保密规定的行 为；公司《2023 ...

证券代码：688351 证券简称：微电生理 公告编号：2023-017 公司 2023 年上半年实际使用募集资金 4,786.52 万元。截至 2023 年 6 月 30 日，募集资金余额为 81,345.69 万元（包括累计收到的银行存款利息扣除银行手 上海微创电生理医疗科技股份有限公司 2023 年半年度募集资金存放与实际使用 情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 根据中国证券监督管理委员会出具的《关于同意上海微创电生理医疗科技股 份有限公司首次公开发行股票注册的批复》（证监许可[2022]1587号），公司向 社会公开发行人民币普通股（A股）7,060万股，发行价格为16.51元/股，募集资 金总额为人民币116,560.60万元，扣除发行费用9,572.61万元后，实际募集资金 净额为106,987.99万元。上述募集资金实际到位时间为2022年8月25日，已经大 华会计师事务所（特殊普通合伙）审验，并出具了《上海微创电生理医疗科 ...

证券代码：688351 证券简称：微电生理 公告编号：2023-019 上海微创电生理医疗科技股份有限公司 关于部分募集资金投资项目新增实施主体的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 上海微创电生理医疗科技股份有限公司（以下简称"公司"）于 2023 年 8 月 17 日召开第三届董事会第四次会议、第三届监事会第四次会议，审议通过了 《关于部分募集资金投资项目新增实施主体的议案》。根据公司首次公开发行股 票募集资金投资项目（以下简称"募投项目"）实施进展及业务发展情况需要， 为进一步降低公司管理运营成本，公司募投项目电生理介入医疗器械研发项目— 肾动脉消融系统项目实施主体拟由公司新增为公司全资子公司上海鸿电医疗科 技有限公司，募投项目其他内容均不发生新增，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意上海微创电生理医疗科技股份有限公 司首次公开发行股票注册的批复》（证监许可[2022]1587 号）核准，公司向社会 公开发行人民币普通股（A 股）7,060 万股，发行价格为 16 ...

证券代码：688351 证券简称：微电生理 公告编号：2023-018 上海微创电生理医疗科技股份有限公司 关于使用暂时闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海微创电生理医疗科技股份有限公司（以下简称"公司"）于 2023 年 8 月 17 日召开第三届董事会第四次会议、第三届监事会第四次会议，审议通过了 《关于使用暂时闲置募集资金进行现金管理的议案》，同意公司拟使用不超过 85,000 万元（含本数）的暂时闲置募集资金（含超募资金）进行现金管理，用于 购买安全性高、流动性好的理财产品或存款类产品，使用期限自公司董事会审议 通过之日起 12 个月内有效。具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意上海微创电生理医疗科技股份有限公 司首次公开发行股票注册的批复》（证监许可[2022]1587 号）核准，公司向社会 公开发行人民币普通股（A 股）7,060 万股，发行价格为 16.51 元/股，募集资金 总额为人民币 116,560.60 万元，扣除发行费 ...

核查意见 华泰联合证券有限责任公司关于 上海微创电生理医疗科技股份有限公司 使用暂时闲置募集资金进行现金管理的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"、"保荐人"）作 为上海微创电生理医疗科技股份有限公司（以下简称"微电生理"或"公司"） 首次公开发行股票并在科创板上市的保荐人及持续督导机构，根据《证券发行上 市保荐业务管理办法》《科创板上市公司持续监管办法（试行）》《上海证券交 易所科创板股票上市规则（2020 年 12 月修订）》《上海证券交易所科创板上市 公司自律监管指引第 1 号——规范运作》《上市公司监管指引第 2 号——上市公 司募集资金管理和使用的监管要求（2022 年修订）》等相关法律、法规和规范 性文件的规定，对微电生理使用部分闲置募集资金（含超募资金）进行现金管理 的事项进行了核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意上海微创电生理医疗科技股份有限公 司首次公开发行股票注册的批复》（证监许可[2022]1587 号）核准，公司向社会 公开发行人民币普通股（A 股）7,060 万股，发行价格为 16.51 元/股，募集资金 总额为人民币 ...

核查意见 华泰联合证券有限责任公司关于 上海微创电生理医疗科技股份有限公司 部分募投项目增加实施主体的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"、"保荐人"）作 为上海微创电生理医疗科技股份有限公司（以下简称"微电生理"或"公司"） 首次公开发行股票并在科创板上市的保荐人及持续督导机构，根据《证券发行上 市保荐业务管理办法》《上海证券交易所科创板股票上市规则（2020 年 12 月修 订）》及《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等相 关法律、法规和规范性文件的规定，对公司增加部分募投项目实施主体的事项进 行了核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意上海微创电生理医疗科技股份有限公 司首次公开发行股票注册的批复》（证监许可[2022]1587 号）核准，公司向社会 公开发行人民币普通股（A 股）7,060 万股，发行价格为 16.51 元/股，募集资金 总额为人民币 116,560.60 万元，扣除发行费用 9,572.61 万元后，实际募集资金净 额为 106,987.99 万元。上述募集资金实际到位时间为 2022 年 8 月 ...

t of the may be and the subject of the subject of the subject of the subject of the subject of the subject of the subject of th 三、关于部分募集资金投资项目新增实施主体的议案 公司本次部分募投项目新增实施主体,符合公司实际经营需要,有利于推动 募投项目的顺利实施,不属于募投项目的实质性变更以及变相改变募集资金用途 的情形,不存在损害公司及全体股东特别是中小股东利益的情形,不会对公司生 产经营造成重大不利影响,审议程序符合相关法律法规和公司《募集资金管理制 度》、《公司章程》等有关规定。我们同意公司本次部分募投项目变更实施主体 的事项。 一、关于使用暂时闲置募集资金进行现金管理的议案 上海微创电生理医疗科技股份有限公司独立董事 关于第三届董事会第四次会议相关议案的独立意见 在保障募集资金安全的前提下,公司使用暂时闲置募集资金(含超募资金) 进行现金管理,用于购买安全性高、流动性好的理财产品或存款类产品。董事会 审议该议案的表决程序合法、有效,符合《上市公司监管指引第2号一上市公司 募集 ...

Financial Performance - The company reported a net profit of RMB 5,982,111.56 for the first quarter of 2023, primarily driven by non-operating income[6]. - The company reported a net loss of ¥9,326,097.49, compared to a net loss of ¥161,475.33 in the previous period, indicating a significant decline in profitability[15]. - The total operating profit was reported at -¥7,326,097.95, a substantial drop from -¥191,475.92 in the prior period[14]. - The total comprehensive loss for the period was ¥9,326,097.49, compared to a loss of ¥161,475.33 in the prior period[15]. - The net profit attributable to shareholders for Q1 2023 was -9,326,097.49 RMB, which is not applicable for comparison[45]. Assets and Liabilities - The total assets of the company as of March 31, 2023, amounted to RMB 1,794,906,439.62, showing a slight increase from RMB 1,788,331,481.27 at the end of 2022[11]. - The total current assets were reported at RMB 1,576,429,271.06, a slight decrease from RMB 1,595,986,425.47 in the previous year[11]. - The company's non-current assets increased to RMB 218,477,168.56 from RMB 192,345,055.80, reflecting a growth of about 13.6%[12]. - The total liabilities of the company as of March 31, 2023, were RMB 78,469,354.86, up from RMB 66,175,646.65, indicating an increase of approximately 18%[12]. - The total liabilities increased to ¥127,116,405.64 from ¥112,837,617.35, showing a growth of 12.6%[21]. - The company's capital reserve increased to ¥1,261,626,105.15 from ¥1,260,003,837.60, reflecting a slight growth of 0.1%[21]. Cash Flow - The company's cash and cash equivalents decreased to RMB 309,988,692.79 from RMB 584,887,873.89 in December 2022, representing a decline of approximately 47%[11]. - The cash inflow from operating activities in Q1 2023 was 72,661,826.96 RMB, compared to 65,483,818.29 RMB in Q1 2022[25]. - The cash outflow from operating activities was 86,449,337.51 RMB, up from 66,284,803.95 RMB in the same period last year[25]. - The company experienced a net cash outflow from investing activities of -¥258,807,625.67, compared to -¥2,879,395.77 in the previous period[17]. - The cash and cash equivalents at the end of the period were ¥302,819,817.79, down from ¥421,807,934.72, indicating a decrease of 28.1%[17]. Revenue and Expenses - The total revenue for Q1 2023 was 52,132,729.40 RMB, representing a decrease of 6.33% year-over-year[45]. - The total operating revenue for Q1 2023 was RMB 52,132,729.40, a decrease from RMB 55,658,087.32 in Q1 2022, representing a decline of approximately 9.1%[57]. - The total operating costs increased to RMB 66,593,648.07 in Q1 2023 from RMB 55,666,530.31 in Q1 2022, indicating a rise of about 19.6%[57]. - Research and development expenses increased to ¥23,452,627.63, up from ¥16,688,365.10, reflecting a 40.5% year-over-year growth[14]. - Research and development expenses totaled 27,001,815.48 RMB, accounting for 51.79% of operating revenue, an increase of 16.03 percentage points from the previous year[29]. - Sales expenses rose to ¥19,950,225.23, compared to ¥15,525,943.11, marking a 28.5% increase[14]. Market Strategy - The company is focusing on expanding its market presence and developing new technologies, although specific details were not disclosed in the report[4].

证券代码：688351 证券简称：微电生理 公告编号：2023-011 上海微创电生理医疗科技股份有限公司 关于召开 2022 年度暨 2023 年第一季度 业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 04 月 19 日(星期三) 至 04 月 25 日(星期二)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 investors@everpace.com 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 上海微创电生理医疗科技股份有限公司（以下简称"公司"）已于 2023 年 3 月 29 日发布公司 2022 年度报告，并将于 2023 年 4 月 22 日发布公司 2023 年第 一季度报告，为便于广大投资者更全面深入地了解公司 2022 年度以及 2023 年第 一季度的经营成果、财务状况，公司计划于 2023 年 0 ...